Programmed cell death, redox imbalance, and cancer therapeutics

被引:50
作者
Dai, Xiaofeng [1 ]
Wang, Danjun [2 ,3 ]
Zhang, Jianying [2 ,3 ]
机构
[1] Jiangnan Univ, Wuxi Sch Med, Wuxi 214122, Jiangsu, Peoples R China
[2] Zhengzhou Univ, BGI Coll, Zhengzhou, Peoples R China
[3] Zhengzhou Univ, Henan Inst Med & Pharmaceut Sci Acad Med Sci, Zhengzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Redox imbalance; Programmed cell death; Cold atmospheric plasma; Cancer therapeutics; PHASE-II TRIAL; PEGYLATED-LIPOSOMAL DOXORUBICIN; COLORECTAL-CARCINOMA CELLS; DEXAMETHASONE COMBINATION THERAPY; EPITHELIAL-MESENCHYMAL TRANSITION; BCL-2 INHIBITOR VENETOCLAX; HUMAN OSTEOSARCOMA CELLS; DOSE-DENSE METHOTREXATE; COLD ATMOSPHERIC PLASMA; NEGATIVE BREAST-CANCER;
D O I
10.1007/s10495-021-01682-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer cells are disordered by nature and thus featured by higher internal redox level than healthy cells. Redox imbalance could trigger programmed cell death if exceeded a certain threshold, rendering therapeutic strategies relying on redox control a possible cancer management solution. Yet, various programmed cell death events have been consecutively discovered, complicating our understandings on their associations with redox imbalance and clinical implications especially therapeutic design. Thus, it is imperative to understand differences and similarities among programmed cell death events regarding their associations with redox imbalance for improved control over these events in malignant cells as well as appropriate design on therapeutic approaches relying on redox control. This review addresses these issues and concludes by bringing affront cold atmospheric plasma as an emerging redox controller with translational potential in clinics.
引用
收藏
页码:385 / 414
页数:30
相关论文
共 546 条
[1]   Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma [J].
Abbasi, MR ;
Sparano, JA ;
Sarta, C ;
Wiernik, PH .
MEDICAL ONCOLOGY, 2003, 20 (01) :53-58
[2]   Vorinostat-loaded titanium oxide nanoparticles (anatase) induce G2/M cell cycle arrest in breast cancer cells via PALB2 upregulation [J].
Abdel-Ghany, Shaimaa ;
Raslan, Sara ;
Tombuloglu, Huseyin ;
Shamseddin, Aly ;
Cevik, Emre ;
Said, Osama A. ;
Madyan, Engy F. ;
Senel, Mehmet ;
Bozkurt, Ayhan ;
Rehman, Suriya ;
Sabit, Hussein .
3 BIOTECH, 2020, 10 (09)
[3]   Redox regulation in cancer A double-edged sword with therapeutic potential [J].
Acharya, Asha ;
Das, Ila ;
Chandhok, Des ;
Saha, Tapas .
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2010, 3 (01) :23-34
[4]   Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo [J].
Ackler, S. ;
Mitten, M. J. ;
Chen, J. ;
Clarin, J. ;
Foster, K. ;
Jin, S. ;
Phillips, D. C. ;
Schlessinger, S. ;
Wang, B. ;
Leverson, J. D. ;
Boghaert, E. R. .
BRITISH JOURNAL OF PHARMACOLOGY, 2012, 167 (04) :881-891
[5]   A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial [J].
Advani, Ranjana H. ;
Ansell, Stephen M. ;
Lechowicz, Mary J. ;
Beaven, Anne W. ;
Loberiza, Fausto ;
Carson, Kenneth R. ;
Evens, Andrew M. ;
Foss, Francine ;
Horwitz, Steven ;
Pro, Barbara ;
Pinter-Brown, Lauren C. ;
Smith, Sonali M. ;
Shustov, Andrei R. ;
Savage, Kerry J. ;
Vose, Julie M. .
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (04) :535-544
[6]   Insight into the Cooperation of P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) at the Blood-Brain Barrier: A Case Study Examining Sorafenib Efflux Clearance [J].
Agarwal, Sagar ;
Elmquist, William F. .
MOLECULAR PHARMACEUTICS, 2012, 9 (03) :678-684
[7]   A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells † [J].
Ahmed, Ahmed Abdullah ;
Neidle, Stephen .
MOLECULES, 2020, 25 (22)
[8]   Synthesis of CDDO-Amino Acid-Nitric Oxide Donor Trihybrids as Potential Antitumor Agents against Both Drug-Sensitive and Drug-Resistant Colon Cancer [J].
Ai, Yong ;
Kang, Fenghua ;
Huang, Zhangjian ;
Xue, Xiaowen ;
Lai, Yisheng ;
Peng, Sixun ;
Tian, Jide ;
Zhang, Yihua .
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (05) :2452-2464
[9]  
Ajani JA, 2002, ONCOLOGY-NY, V16, P89
[10]   Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer [J].
Albrecht, W ;
Van Poppel, H ;
Horenblas, S ;
Mickisch, G ;
Horwich, A ;
Serretta, V ;
Casetta, G ;
Maréchal, JM ;
Jones, WG ;
Kalman, S ;
Sylvester, R .
BRITISH JOURNAL OF CANCER, 2004, 90 (01) :100-105